Labcorp (LH) recently announced the commercial availability of its new H5 bird flu molecular test in the United States. The test will help physicians diagnose patients suspected of infection with the H5N1 virus.The test was developed in collaboration with the CDC (Centers for Disease Control and Prevention) to support public health preparedness strategies.LH Stock’s Likely Trend Following the NewsSince the announcement on Dec. 17, Labcorp shares have fallen 2%, finishing at $226.31 yesterday. On a promising ...